Guoqing Li
Vendite & Marketing presso Golden Maple Leaf Enterprises, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Liren Tang | M | - |
Welichem Biotech, Inc.
 Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 15 anni |
| Lei Lv | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 12 anni |
| Michael Lyle | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 15 anni |
| Ryan B. Zeng | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 10 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Xiang Dong Tan | M | 69 |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 4 anni |
| Jane Yue | F | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 2 anni |
| Harvey S. K. Quan | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Genhui Chen | M | 60 |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| York Yingping Guo | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Lijuan Pang | F | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 2 anni |
| Wen Feng Liu | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | 1 anni |
| Meilin Yi | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| Jianke Yang | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
| James Dai | M | - |
Welichem Biotech, Inc.
Welichem Biotech, Inc. Pharmaceuticals: MajorHealth Technology Welichem Biotech, Inc. operates as a drug discovery and early stage drug development company focusing on novel therapeutics for autoimmune, inflammatory diseases and cancers. The firm's focus has been on research and development of its novel anti-inflammatory drug candidate, WBI-1001 and its derivatives, and its anticancer drug candidate, WBI-2100 and its derivatives. The company was founded on November 1, 2004 and is headquartered in Burnaby, Canada. | - |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Canada | 14 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Guoqing Li
- Contatti personali
